| Name | TMX-201 |
|---|
| Description | TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research[1]. |
|---|---|
| Related Catalog | |
| Target |
TLR7 |
| In Vitro | TMX-201 is more potent cytokine inducer than Imiquimod (HY-B0180) in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod[1]. |
| In Vivo | The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg[1]. TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects[1]. TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model[1]. |
| References |
| Molecular Formula | C57H93N6O12P |
|---|---|
| Molecular Weight | 1085.36 |